Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine

Completed · Phase 2

Conditions studied: Meningococcal Meningitis, Meningococcal Infections

In brief

The purpose of this study is to evaluate the production of antibodies to a new conjugate vaccine, NmVac4-A/C/Y/W-135-DT, as a measure of vaccine effectiveness, compared to the production of antibodies to a similar, licensed meningococcal (Groups A, C, Y, W-135) polysaccharide diphtheria toxoid (DT) conjugate vaccine. The investigators will also evaluate the safety of NmVac4-A/C/Y/W-135-DT™ conjugate vaccine compared to the licensed vaccine. The hypothesis is that the test vaccine is comparable to the licensed active control vaccine.

Key facts

Study ID

NCT01897402

Run by

JN-International Medical Corporation

People needed

525

Starts

2013-07-01

Expected to finish

2014-12-01

Last updated by the study team

2015-04-23

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

Where it is running

• Mid Atlantic Urology Associates LLC — Greenbelt, Maryland, United States
• Chesapeake Research Group — Pasadena, Maryland, United States
• IRC Clinics — Towson, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.